Farnesylated prelamin A is a processing intermediate produced in the lamin A maturation pathway. Accumulation of a truncated farnesylated prelamin A form, called progerin, is a hallmark of the severe premature ageing syndrome, Hutchinson-Gilford progeria. Progerin elicits toxic effects in cells, leading to chromatin damage and cellular senescence and ultimately causes skin and endothelial defects, bone resorption, lipodystrophy and accelerated ageing. Knowledge of the mechanism underlying prelamin A turnover is critical for the development of clinically effective protein inhibitors that can avoid accumulation to toxic levels without impairing lamin A/C expression, which is essential for normal biological functions. Little is known about specific molecules that may target farnesylated prelamin A to elicit protein degradation. Here, we report the discovery of rapamycin as a novel inhibitor of progerin, which dramatically and selectively decreases protein levels through a mechanism involving autophagic degradation. Rapamycin treatment of progeria cells lowers progerin, as well as wild-type prelamin A levels, and rescues the chromatin phenotype of cultured fibroblasts, including histone methylation status and BAF and LAP2alpha distribution patterns. Importantly, rapamycin treatment does not affect lamin C protein levels, but increases the relative expression of the prelamin A endoprotease ZMPSTE24. Thus, rapamycin, an antibiotic belonging to the class of macrolides, previously found to increase longevity in mouse models, can serve as a therapeutic tool, to eliminate progerin, avoid farnesylated prelamin A accumulation, and restore chromatin dynamics in progeroid laminopathies.

Autophagic degradation of farnesylated prelamin A as a therapeutic approach to lamin-linked progeria / Cenni, V; Capanni, C; Columbaro, M; Ortolani, M; D'Apice, Mr; Novelli, G; Fini, M; Marmiroli, Sandra; Scarano, E; Maraldi, Nm; Squarzoni, S; Prencipe, S; Lattanzi, G.. - In: EUROPEAN JOURNAL OF HISTOCHEMISTRY. - ISSN 1121-760X. - ELETTRONICO. - 55:e36:4(2011), pp. 200-205. [10.4081/ejh.2011.e36]

Autophagic degradation of farnesylated prelamin A as a therapeutic approach to lamin-linked progeria.

MARMIROLI, Sandra;
2011

Abstract

Farnesylated prelamin A is a processing intermediate produced in the lamin A maturation pathway. Accumulation of a truncated farnesylated prelamin A form, called progerin, is a hallmark of the severe premature ageing syndrome, Hutchinson-Gilford progeria. Progerin elicits toxic effects in cells, leading to chromatin damage and cellular senescence and ultimately causes skin and endothelial defects, bone resorption, lipodystrophy and accelerated ageing. Knowledge of the mechanism underlying prelamin A turnover is critical for the development of clinically effective protein inhibitors that can avoid accumulation to toxic levels without impairing lamin A/C expression, which is essential for normal biological functions. Little is known about specific molecules that may target farnesylated prelamin A to elicit protein degradation. Here, we report the discovery of rapamycin as a novel inhibitor of progerin, which dramatically and selectively decreases protein levels through a mechanism involving autophagic degradation. Rapamycin treatment of progeria cells lowers progerin, as well as wild-type prelamin A levels, and rescues the chromatin phenotype of cultured fibroblasts, including histone methylation status and BAF and LAP2alpha distribution patterns. Importantly, rapamycin treatment does not affect lamin C protein levels, but increases the relative expression of the prelamin A endoprotease ZMPSTE24. Thus, rapamycin, an antibiotic belonging to the class of macrolides, previously found to increase longevity in mouse models, can serve as a therapeutic tool, to eliminate progerin, avoid farnesylated prelamin A accumulation, and restore chromatin dynamics in progeroid laminopathies.
55
4
200
205
Autophagic degradation of farnesylated prelamin A as a therapeutic approach to lamin-linked progeria / Cenni, V; Capanni, C; Columbaro, M; Ortolani, M; D'Apice, Mr; Novelli, G; Fini, M; Marmiroli, Sandra; Scarano, E; Maraldi, Nm; Squarzoni, S; Prencipe, S; Lattanzi, G.. - In: EUROPEAN JOURNAL OF HISTOCHEMISTRY. - ISSN 1121-760X. - ELETTRONICO. - 55:e36:4(2011), pp. 200-205. [10.4081/ejh.2011.e36]
Cenni, V; Capanni, C; Columbaro, M; Ortolani, M; D'Apice, Mr; Novelli, G; Fini, M; Marmiroli, Sandra; Scarano, E; Maraldi, Nm; Squarzoni, S; Prencipe, S; Lattanzi, G.
File in questo prodotto:
File Dimensione Formato  
AUTOPHAGIC DEGRADATION ejh-2011-4-e36.pdf

accesso aperto

Tipologia: Post-print dell'autore (bozza post referaggio)
Dimensione 1.03 MB
Formato Adobe PDF
1.03 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/708824
Citazioni
  • ???jsp.display-item.citation.pmc??? 53
  • Scopus 65
  • ???jsp.display-item.citation.isi??? 64
social impact